Speaker Information

2013 Molecular Medicine Tri-Conference Speaker & Panelists* 

• Adam Kraut, Scientific Consultant, BioTeam, Inc. 
• Adam Margolin, Ph.D., Computational Biology, Sage Bionetworks  
• Alan F. Feeney, Esq., Owner, Feeney Law Group 
• Alex Cho, M.D., MBA, Assistant Professor, Department of Medicine, General Internal Medicine, DUHS Center for Personalized Medicine, Duke University  
• Alexander Dobrovic, M.D., Head, Molecular Pathology R&D, Pathology, Peter MacCallum Cancer Centre 
• Ajay Shah, Ph.D., Director, Research Informatics Division, City of Hope 
• Akash Kumar, B.Chem.E, M.S., M.D./Ph.D. Candidate, Genome Sciences, University of Washington 
• Alan Carter, Chief Business Officer, PanGenX 
• Alex Cho, M.D., MBA, Assistant Professor, Department of Medicine, General Internal Medicine, DUHS Center for Personalized Medicine, Duke University  
• Alexander Morley, M.D., Professor, Head, Minimal Residual Disease Group, Haematology & Genetic Pathology, Flinders University 
• Alexandra S. Whale, Ph.D., Researcher, LCG Ltd. 
• Ali Tinazli, Ph.D., Director, Business Development & Sales, Sony DADC  
• Alice Jacobs, Ph.D., Chairman & CEO, IntelligentMDx 
• Alison Betts, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism (PDM), Pfizer Worldwide Research & Development 
• Allan T. Bombard, M.D., CMO, Sequenom 
• Andrea L. Richardson, M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Department of Cancer Biology, Dana-Farber Cancer Institute; Senior Staff Pathologist, Brigham and Women’s Hospital, Department of Pathology  
• Andreas M. Kogelnik, M.D., Ph.D., Director, Open Medicine Institute 
• Andreas Matern, Vice President, Disruptive Innovation, Thomson Reuters 
• Andrew Dallas, President & CTO, Full Spectrum Software, Inc. 
• Andrew Poklepovic, Ph.D., Assistant Professor, Internal Medicine, Virginia Commonwealth University  
• Andro Hsu, Ph.D., Vice President, Products, GigaGen, Inc. 
• Anil Sethi, CEO, Pinch Bio; HL7 Pioneer and Health Informatics Entrepreneur 
• Anil V. Parwani, M.D., Ph.D., Director, Division of Pathology Informatics, University of Pittsburgh  
• Apostolia-Maria Tsimberidou, M.D., Ph.D., Associate Professor, Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center 
• Arnon Chait, Ph.D., President, AnalizaDx, LLC 
• Arthur L. Beaudet, M.D., Henry and Emma Meyer Professor and Chair, Department of Molecular and Human Genetics, Baylor College of Medicine 
• Arturo Morales, Ph.D., Global Leader Data Federation Initiative, Informatics Systems Lead, Novartis   
• Arun Nayar, Global Head, External Collaborations, R&D, Information, AstraZeneca Pharmaceuticals 
• Asuncion Mejias, M.D., Principal Investigator, Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital 
• Athena Cherry, Ph.D., Director, Cytogenetics Laboratory; Professor, Pathology and Pediatrics, Stanford Comprehensive Cancer Center 
• Austin Tanney, Ph.D., Scientific Liaison Manager, Almac Group 
• Ayub Khattak, CEO, Ruubix, Inc. 
• Balaji Panchapakesan (Baloo), Ph.D., Associate Professor of Mechanical Engineering, University of Louisville  
• Barry Bunin, Ph.D. CEO, Collaborative Drug Discovery 
• Barry Hart, Ph.D., VP, Project Mgmt. & Business Development, Allostem Therapeutics 
• Birgit H. Funke, Ph.D., FACMG, Assistant Professor of Pathology, MGH/Harvard Medical School; Director of Clinical Research and Development, Laboratory for Molecular Medicine, PCPGM  
• BJ Kerns, SVP, Translational Medicine, HTG Molecular Diagnostics, Inc. 
• Bob S. Carter M.D., Ph.D., Professor and Division Chief, UCSD Neurosurgery  
• Borna Safabakhsh, Co-Founder and CEO, Agile Diagnosis  
• Branimir I. Sikic, M.D., Professor of Medicine, Division of Oncology, Stanford University School of Medicine 
• Brian K. Albrecht, Ph.D., Sr. Dir., Medicinal Chemistry, Constellation Pharmaceuticals  
• Brian T. Edmonds, Ph.D., Research Advisor, Global External Research & Development, Lilly Corporate Center 
• Bruce K. Gale, Ph.D., Associate Professor and Director, State of Utah Center of Excellence for Biomedical Microfluidics, Department of Mechanical Engineering, University of Utah 
• Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist. Life Science & Government Strategy & Medical Coverage & Reimbursement, Foley Hoag 
• Bruce R. Korf, M.D., Ph.D., Wayne H. and Sara Crews Finley Chair in Medical Genetics; Professor and Chair, Department of Genetics; Director, Heflin Center for Genomic Sciences, University of Alabama at Birmingham 
• BS Manjunath, Director, Center for Bio-image Informatics; Vice Chair and Undergraduate Program Director, Department of Electrical and Computer Engineering, University of California Santa Barbara  
• Byron C. Hann, M.D., Ph.D., Associate Researcher, Manager of Pre-Clinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center 
• C. Glenn Begley, Ph.D., Senior Vice President, TetraLogic 
• Calvin B. Harley, Ph.D., CSO, Telome Health, Inc. 
• Carlos Cordon-Cardo, M.D., Ph.D., Professor and Chairman, Department of Pathology; Professor, Department of Genetics and Genomic Sciences, The Mount Sinai School of Medicine 
• Carol Bova Hill, Ph.D., Informatics Project Leader II, Clinical Research Informatics, Duke Clinical Research Institute  
• Casey Eitner, Senior Vice President, Business Development, Vitatex, Inc. 
• Cedo Bagi, M.D., Ph.D., Senior Research Fellow, Worldwide Comparative Medicine, Global Science & Technology, Pfizer Global R&D 
• Cecilia Schott, Pharm.D., M.B.A., Executive Business Development Director, Personalized Healthcare, AstraZeneca 
• Cha-Mei Tang, Sc.D., President and CEO, Creatv MicroTech, Inc. 
• Chaminda Selgado, Ph.D., Head of Department, CMC Bioassay & Genomics, NDA-Analytics 
• Charles Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen 
• Chiang J. Li, M.D., FACP, President, CEO & CMO, Boston Biomedical, Inc; Head, Global Oncology, Dainippon Sumitomo Pharma Group 
• Chris Higgs, Senior Applications Scientist, Schrodinger 
• Chris L. Waller, Ph.D., Director, Cheminformatics, Discovery Merck Research Labs  
• Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group 
• Christina Lu, Manager, IT, Novartis Pharmaceuticals Corp.  
• Christine M. Eng, M.D., Professor, Department of Molecular and Human Genetics, Baylor College of Medicine 
• Christopher A. Moskaluk, M.D., Ph.D., David Harrison Distinguished Teaching Professor of Pathology, University of Virginia Health System 
• Christopher J. O’Donnell, Ph.D., Sr. Director, Oncology Medicinal Chemistry, Pfizer 
• Claude Dufresne, Ph.D., Director, Business Development, Scienion US, Inc. 
• Clay Marsh, M.D., Executive Director, Center for Personalized Health Care; Vice Dean and Senior Associate Vice President, Research, College of Medicine; Professor, Internal Medicine, Pulmonary, Allergy, Critical Care and Sleep Medicine; Director, Center for Critical Care and Respiratory Medicine, Ohio State University Medical Center 
• Cleland C. Landolt, M.D., CMO, Singulex, Inc. 
• Corrado Priami, Ph.D., President and CEO, The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI) 
• Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center 
• Dan Roden, M.D., Assistant Vice Chancellor of Personalized Medicine, Vanderbilt University  
• Daniel Danila, M.D., Genitourinary Oncology Service, Department of Medicine,Memorial Sloan-Kettering Cancer Center   
• Daniel Haber, M.D., Ph.D., Director, Massachusetts General Hospital Cancer, Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute 
• Daniel Hayes, M.D., Professor, Internal Medicine, University of Michigan, Ann Arbor  
• Daniel MacArthur, Ph.D., Group Leader, Analytic and Translational Genetics Unit, Massachusetts General Hospital  
• Daniëlle A.M. Heideman, Ph.D., Assistant Professor, Department of Pathology, Molecular Pathology Unit, VU University Medical Center  
• Darrell Dinwiddie, Ph.D., Director, Lab Operations, Center for Pediatric Genomic Medicine, Children’s Mercy Hospitals and Clinics  
• David A. Flockhart, M.D., Ph.D.,  Harry and Edith Gladstein Chair in Cancer Genomics, Professor of Medicine, Genetics and Pharmacology; Director, Division of Clinical Pharmacology, Indiana Institute for Personalized Medicine  
• David A. Lawrence, Ph.D., Chief, Laboratory of Immunology, Wadsworth Center, NYSDOH  
• David A. Spiegel, Ph.D., Associate Professor of Chemistry, Yale  
• David C. Wilbur, M.D., Professor, Pathology, Harvard Medical School and Massachusetts General Hospital  
• David Dimmock, M.D., Assistant Professor, Pediatrics, Medical College of Wisconsin 
• David Fung, Ph.D., Postdoctoral Research Fellow, School of Biotechnology and Biomolecular Sciences, The University of New South Wales 
• David G. Hicks, M.D., FCAP, Professor and Director, Surgical Pathology Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center  
• David Huntsman, M.D., FRCPC, FCCMG, Medical Director, Center for Translational & Applied Genomics, British Columbia Cancer Agency  
• David Jackson, Vice President, Business Development, PrimeraDx 
• David L. Dolinger, Ph.D., Executive Vice President, Business Development & Technology Realization, Seegene, Inc. 
• David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University  
• David A. Spiegel, Ph.D., Associate Professor of Chemistry, Yale 
• David Steinmiller, Founder & COO, Claros Diagnostics 
• David Tarin, M.D., Ph.D., Professor of Pathology, Director, UCSD Comprehensive Cancer Center   
• Deepak Rajpal, Ph.D., Senior Scientific Investigator, Computational Biology, Medicines Discovery & Development, GlaxoSmithKline 
• Dehua Pei, Ph.D., Professor of Chemistry and Biochemistry, The Ohio State University 
• Dietrich Stephan, Ph.D., Founder & CEO, Silicon Valley Biosystems (SVBio) 
• Dimitris Agrafiotis, Janssen R&D, Johnson & Johnson 
• Dirk Vossen, Ph.D., Director, Applications and Q&R, Philips Digital Pathology  
• Donald Berry, Ph.D., Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center 
• Dylan Morris, Co-Founder, Integrated Plasmonics Corporation 
• Ed Olhava, Ph.D., Associate Director, Pre-Clinical Development, Epizyme, Inc. 
• Edward Abrahams, President, Personalized Medicine Coalition 
• Edward Holson, Ph.D., Director, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard 
• Elizabeth Bruckheimer, Ph.D., Vice President Scientific Operations, Champions Oncology, Inc. 
• Elisabeth Paietta, Ph.D., Professor of Medicine, Albert Einstein College of Medicine, Director, ECOG Leukemia Translational Research Laboratory and Leukemia Tissue Bank, Montefiore Medical Center-North Division 
• Elizabeth A. Krupinski, Ph.D., Professor & Vice Chair of Research, Department of Medical Imaging, University of Arizona  
• Elizabeth Farrant, Ph.D., Chief Business Officer, Cyclofluidic Ltd 
• Elizabeth Worthey, Assistant Professor, Pediatrics & Bioinformatics Program, Human & Molecular Genetics Center, Medical College of Wisconsin  
• Emma Lees, Ph.D., Vice President, Oncology, NIBR Site Head Emeryville, Novartis Institutes for Biomedical Research 
• Eric A. Murphy, Ph.D., Research Investigator in Oncology Pharmacology Genomics Institute of the Novartis Research Foundation 
• Eric F. Glassy, M.D., Medical Director, Pathology, Inc.  
• Eric Rubin, M.D., Vice President, Clinical Research Oncology, Merck 
• Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc. 
• Erik Douglas, Co-Founder and CEO, CellScope 
• Eugene Zhukovsky, Ph.D., CSO, Research, Affimed Therapeutics AG 
• Evian Gordon, M.D., CEO, Brain Resource Company Limited  
• Frank Diehl, Ph.D., Managing Director, Chief Scientific Officer, Inostics GmbH 
• Frank Lovering, Ph.D., Principle Scientist II, Computational Chemistry, Pfizer 
• Frank Pajonk, M.D., Ph.D., Associate Professor, Radiation Oncology, David Geffen School of Medicine, University of California Los Angeles 
• Fred Russell Kramer, Ph.D., Professor, Department of Microbiology and Molecular Genetics, Public Health Research Institute, New Jersey Medical School 
• Fredika Robertson, Ph.D., Professor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center  
• G. Mike Makrigiorgos, Ph.D., Director, Biophysics Laboratory and Medical Physics Division, Dana Farber Cancer Institute, Harvard Medical School  
• Gaddy Getz, Director, Cancer Genome Computational Analysis, Broad Institute  
• Gallen Triana-Baltzer, Ph.D., Senior Scientist, Oncology, CovX Research, Pfizer WRD  
• Gary Clawson, M.D., Penn State University at Hershey Medical Center 
• George I. Mias, Ph.D., Postdoctoral Scholar, Snyder Lab, Department of Genetics, Stanford University School of Medicine
• German Pihan, M.D., Director, Hematopathology Lab, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School 
• Glenn A. Miller, Ph.D., Vice President and Head, Personalized Healthcare and Biomarkers, Strategy, Portfolio and Alliances, AstraZeneca Pharmaceuticals LP  
• Gordon Springer, Ph.D., Scientific Director, Department of Computer Science, University of Missouri Bioinformatics Consortium 
• Gorm Lisby, M.D.,  Ph.D., Senior Vice President, CSO, Science & Development, QuantiBact, Inc. (tentative) 
• Graeme Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals, Inc. 
• Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center 
• Gregory Zdechlik, COO, Eli Lilly & Co. 
• Guoqing “GC” Chen, Ph.D., Vice President, Research, Biology, Igenica, Inc. 
• Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic Medical Center 
• Haifeng Bao, Principal Scientist, Research & Development Translational Sciences, MedImmune 
• Hakan Sakul, Ph.D., Executive Director & Head, Diagnostics, Worldwide Research & Development, Clinical Research and Precision Medicine, Pfizer, Inc.  
• Hakon Hakonarson, M.D., Ph.D., Director, Center for Applied Genomics, Children’s Hospital of Philadelphia  
• Handan He, Ph.D., Dir., Pre-Clinical PK/PD, DMPK, Translational Sciences, Novartis 
• Hannah Mamuszka, Vice President, Business Development, Exosome Diagnostics  
• Hans-Peter Gerber, Ph.D., Executive Director, BioConjugate Discovery and Development, Oncology Research Unit East, Pfizer Worldwide R&D 
• Harry Glorikian, Founder and Managing Partner, Scientia Advisors 
• Harsukh Parmar, M.D., Vice President and Head, Translational and Experimental Medicine, F. Hoffmann La Roche 
• Heidi L. Rehm, Ph.D., FACMG, Assistant Professor, Pathology, BWH and Harvard Medical School; Director, Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine  
• Herbert Haack, Ph.D., Head, Clinical Assay Development, Cell Signaling Technology 
• Holbrook Kohrt, M.D., Ph.D., Assistant Professor, Oncology, University of Stanford 
• Holger Wesche, Ph.D., Principal Scientist, Amgen, Inc. 
• HongMei Huang, Ph.D., Director and Site Head, NIBR IT Emeryville, Novartis  
• Hsian-Rong Tseng, Ph.D., Associate Professor, Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, Institute for Molecular Medicine, University of California, Los Angeles; California NanoSystems Institute  
• Huimin Kong, Ph.D., President & CEO, BioHelix Corp. 
• Iman Jilani, Ph.D., Associate Director, Clinical Assay Group, Global Clinical Pharmacology, Pfizer, Inc.  
• Irina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis NCI, NIH 
• Iris Schrijver, M.D., Associate Professor of Pathology and Pediatrics; Director, Molecular Pathology Laboratory, Stanford University Medical Center, Lucile Packard Children’s Hospital 
• Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S 
• Jacob Glanville, Ph.D., Science Director, Distributed Bio 
• James C. Willey, M.D., Professor, Medicine and Pathology, University of Toledo College of Medicine; Consultant, Accugenomics, Inc. 
• James Linder, M.D., Senior Associate to the President for Innovation and Economic Competitiveness; President, University Technology Development Corp.; Professor, Pathology and Microbiology, University of Nebraska 
• Jamey Skillings, M.D., Vice President, Global Medical Affairs, Pfizer 
• Jamie MacPherson, Ph.D., Consultant, Tessella 
• Jamie Timmons, Ph.D., Professor, Systems Biology, Loughborough University 
• Jan Lötvall, M.D., Ph.D., Professor, Chairman, Krefting Research Centre; President, International Society for Extracellular Vesicles (ISEV)  
• Jane Reese-Coulbourne, MS, ChE, Executive Director, Reagan-Udall Foundation for the FDA; Former Board Chair, Lung Cancer Alliance; Cancer Survivor 
• Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc. 
• Jason Wakizaka, Co-Founder and Managing Member, LifeLens LLC 
• Jay Bergeron, Program Manager, Pfizer 
• Jaya Goyal, Ph.D., Principal Investigator, Translational Medicine, Biogen Idec 
• Jean-Louis Viovy, Research Director, Macromolecules and Microsystems in Biology and Medicine Lab, Institute Curie   
• Jeffrey J. Chalmers, Ph.D., Professor, Chemical & Biomolecular Engineering; Director, Analytical Cytometry Shared Resource, The Ohio State University Comprehensive Cancer Center  
• Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech 
• Jennie Mather, Senior Vice President, Stem Cell Technologies, Macrogenics, Inc. 
• Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation 
• Jeremy Packer, Ph.D., Principal Research Scientist, Scientific Informatics, Abbott Laboratories  
• Jian Han, M.D., Ph.D., Faculty Investigator, HudsonAlpha Institute for Biotechnology, Director, R10K Project  
• Jian Yu Rao, M.D., Professor, Pathology and Laboratory Medicine, UCLA Program on Genomics and Nutrition 
• Jian Wang, Ph.D., President & CEO, BioFortis, Inc. 
• Jim Hendler, Ph.D., Tetherless World Professor of Computer and Cognitive Science and Assistant Dean of Information Technology and Web Science, Rennselaer Polytechnic Institute  
• Jing Wu, M.D., Ph.D., Assistant Professor, Department of Neurology and Neurosurgery; Co-Director, Neuro-Oncology Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina  
• Joe W. Gray, Ph.D., Gordon Moore Professor and Chair, Biomedical Engineering, Oregon Health and Science University; Emeritus Professor, UCSF; Visiting Faculty, Lawrence Berkeley National Laboratory; Co-Director, Breast Cancer SPORE 
• John Aletta, Ph.D., Principle Scientist, CH3 Biosystems LLC 
• John F. Beeler, Ph.D., Director, Theranostics & Business Development, bioMerieux 
• John Doukas, Ph.D., Senior Director, Pre-Clinical Safety and Efficacy, Vical, Inc.  
• John Flygare, Ph.D., Senior Scientist, Discovery Chemistry, Genentech  
• John Hunter, Ph.D., Vice President, Antibody Research & Development, Compugen, Inc. 
• John Iafrate, M.D., Ph.D., Assistant Professor, Pathology, Harvard Medical School; Assistant Pathologist, Massachusetts General Hospital 
• John McDonough, CEO & President, T2 Biosystems  
• John Swart, Ph.D., President, Exemplar Genetics 
• John Terrett, Ph.D., CSO, Oxford Biotherapeutics, Inc.  
• John S. Yu, M.D., Professor & Vice Chairman, Neurosurgery, Cedars-Sinai Medical Center; Chairman & CSO, ImmunoCellular Therapeutics 
• Jonas Boström, Ph.D., Computational Chemist, Medicinal Chemistry, AstraZeneca 
• Jonas Winchell, Ph.D., Laboratory Chief, Pneumonia Response and Surveillance Laboratory, Division of Bacterial Diseases, Respiratory Diseases Branch, Centers for Disease Control and Prevention (CDC) 
• Jonathan Cheng, M.D., Director, Oncology Clinical Development, Merck 
• Jonathan Lim, Ph.D., CEO, NexDx, Inc. 
• Jonathan Pachter, Ph.D., Vice President & Head, Research, Verastem, Inc. 
• Jonathan S. Mason, Ph.D., Drug Design & Computational Chemistry, Heptares Therapeutics Ltd. 
• Jorge DiMartino, M.D., Ph.D., Executive Director, Translational Development, Celgene Corporation
• Joseph M. Beechem, Ph.D., Senior Vice President, Research & Development, NanoString Technologies 
• Joseph F. Donahue, Senior Vice President, Intellectual Property & Science, Thomson Reuters 
• Joseph Szustakowski, Ph.D., Senior Group Head, Bioinformatics, Biomarker Discovery, Novartis Institutes for BioMedical Research 
• Joshua Mandel, M.D., S.B. Research Faculty, Harvard Medical School/Children’s Hospital Informatics Program; Lead Architect for the SMART project, Harvard Medical School/Office of the National Coordinator for Health IT  
• Joshua Stuart, Ph.D., Associate Professor, Department of Biomolecular Engineering, University of California Santa Cruz 
• Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc. 
• Jutta Deckert, Ph.D., Principal Scientist, Discovery Research, ImmunoGen, Inc. 
• Kahn Rhrissorrakrai, Ph.D., Post-doctoral Researcher, Functional Genomics and Systems Biology, IBM Thomas J. Watson Research Center 
• Karl Voelkerding, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Advanced Technology & Bioinformatics, ARUP Laboratories 
• Kathryn Teng, M.D., FACP, Director, Center for Personalized Healthcare, Cleveland Clinic 
• Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies 
• Keith James, Vice President, Therapeutic Innovation, The Ferring Research Institute; Visiting Investigator, The Scripps Research Institute 
• Keith Kaplan, M.D., Pathologist and CIO, Carolinas Pathology Group  
• Kenneth E. Pierce, Ph.D., Senior Research Scientist, Department of Biology, Brandeis University 
• Kenneth J. Bloom, M.D., CMO, Clarient, Inc.  
• Kevin Bobofchak, Ph.D., Pathway Studio Product Manager, Elsevier 
• Kevin Davies, Ph.D., Chief Editor, Bio-IT World   
• Kim Nguyen, Ph.D., Head, Research, Quantum Cell Expansion System, Terumo BCT 
• Kimberle C. Chapin, M.D., Lifespan Academic Medical Centers and Brown Medical School 
• Klaus Pantel, M.D., Director, Institute of Tumor Biology, UKE 
• Koen Van Acker, Ph.D., Scientist, Research & Assay Development, Biocartis NV 
• Kristen M. Smith, Ph.D., Scientist II, Bionomics, Inc. 
• Kristin Pothier, Founder, DxInsights; Partner, Health Advances  
• Larry J. Lesko, Ph.D., FCP, Professor, Department of Pharmaceutics, University of Florida College of Pharmacy 
• Laura J. Tafe, M.D., Assistant Director, Molecular Pathology; Assistant Professor, Department of Pathology, Dartmouth-Hitchcock Medical Center 
• Laura Jean Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology, University of California San Francisco 
• Laurence Marton, M.D., Adjunct Professor, Department of Laboratory Medicine, University of California San Francisco; Former Dean 
• Leanna Levine, Ph.D., President and CEO, ALine, Inc. 
• Leming Shi, Ph.D., National Center for Toxicological Research, U.S. Food and Drug Administration  
• Len Koenig, Senior Research Associate Research Computing, Computer Science and Chemistry, ExxonMobil Research and Engineering 
• Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc. 
• Leslie Crews Robertson, Ph.D., Jamieson Laboratory, Sanford Consortium for Regenerative Medicine & Moores UC San Diego Cancer Center 
• Lewis Frey, Ph.D., Assistant Professor, Biomedical Informatics, University of Utah 
• Lily Kong, CSO, PrimeraDx 
• Liron Pantanowitz, M.D., Associate Professor of Pathology, University of Pittsburgh Medical Center; Department of Pathology, UPMC Shadyside  
• Luis Diaz, M.D., Associate Professor of Oncology, Director of Translational Medicine, Ludwig Center at Johns Hopkins, Kimmel Cancer Center at Johns Hopkins  
• Luis F. Parada, Ph.D., Diana K. and Richard C. Strauss Distinguished Chair in Developmental Biology, Southwestern Ball Distinguished Chair in Nerve Regeneration Research, University of Texas Southwestern Medical Center 
• Lukas Karlsson, Head, Administrative Computing, Technology Leader Broad Institute  
• Lynn R. Zieske, Ph.D., Vice President, Commercial Solutions, Singulex, Inc. 
• Madhuri Hegde, Ph.D., FACMG, Associate Professor, Senior Director, Emory Genetics Laboratory, Department of Human Genetics, Emory University School of Medicine 
• Maham Ansari, MS, RAC, Senior Associate, Regulatory Affairs, Strategic Regulatory Services, OptumInsight, Inc. (UnitedHealth Group) 
• Manish Muzumdar, Senior Vice President, Products, Remedy Informatics 
• Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare 
• Marcin Imielinski, M.D., Ph.D., Pathology, Brigham and Women’s Hospital; Meyerson Lab, Broad Institute and Dana Farber Cancer Institute 
• Marco L. Schito, Ph.D. (contractor), Henry M. Jackson Foundation, Vaccine Clinical Research Branch, DAIDS, NIAID, NIH 
• Marco Timmers, Ph.D., Vice President, NCEs, Biopharmaceuticals, Synthon BV 
• Maria Vassileva, Ph.D., Scientific Program Manager, Metabolic Disorders, The Biomarkers Consortium 
• Mark A. Collins, Ph.D., Director, Marketing, BioFortis, Inc. 
• Mark A. DePristo, Ph.D., Associate Director, Medical and Population Genetics Analysis, Broad Institute of MIT and Harvard (on behalf of The 1000 Genomes Project Consortium) 
• Mark A. Musen, M.D., Ph.D., Professor of Medicine, Biomedical Informatics, Stanford Center for Biomedical Informatics Research 
• Mark L. Peterson, Ph.D., Vice President, Operations, Tranzyme Pharma 
• Mark S. Boguski, Ph.D., Associate Professor, Center for Biomedical Informatics, Harvard Medical School 
• Mark Zak, Ph.D., Scientist, Discovery Chemistry, Genentech 
• Martin Baatz, Ph.D., Vice President, Marketing, Definiens 
• Martin Leach, Ph.D., CIO, The Broad Institute 
• Martin G. Reese, President and CEO, Omicia, Inc. 
• Martin Seifert, Ph.D., CEO, Genomatix Software 
• Marty Tenenbaum, Ph.D., Founder and Chairman, Cancer Commons; Prominent AI Researcher; Cancer Survivor 
• Mary Bradley, Ph.D., MBA, CollaborationFinder 
• Mats Grahn, CEO, Immunovia AB 
• Matthew P. Jacobson, Ph.D., Professor, Pharmaceutical Chemistry, Department of Bioengineering and Therapeutic Science, University of California San Francisco 
• Maureen Cronin, Ph.D., Industry Consultant 
• Max S. Wicha, M.D., Distinguished Professor of Oncology and Director, University of Michigan Comprehensive Cancer Center  
• Medical Oncology, The University of Texas MD Anderson Cancer Center 
• Melissa R. Junttila, Ph.D., Scientist, Molecular Biology, Genentech, Inc. 
• Mic Lajiness, Ph.D., Research Advisor, Eli Lilly  
• Michael Barrett, Ph.D., Associate Professor, Clinical Translational Research Division; Unit Head, Oncogenomics Laboratory, TGEN 
• Michael Detmar, M.D., Professor of Pharmacogenomics, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich 
• Michael Fero, Ph.D., CEO, TeselaGen Bio 
• Michael Foley, Ph.D., Director, Chemical Biology, Broad Institute  
• Michael Roehrl, M.D., Ph.D., Associate Professor of Pathology, University of Toronto 
• Michael Schwartz, Program Director, Business Development, Fluxion Biosystems, Inc. 
• Michael Webb, CEO, Allegro Diagnostics, Inc. 
• Michele Babicky, M.D., Department of Surgery, University of California San Diego  
• Michelle R. Arkin, Ph.D., Associate Adjunct Professor, Pharmaceutical Chemistry, University of California San Francisco School of Pharmacy 
• Mick Bhatia, Ph.D., Director and Senior Scientist, McMaster Stem Cell and Cancer Research Institute, McMaster University 
• Mike Cummens, M.D., Chief Medical Officer, Remedy Informatics 
• Mike Elliott, Ph.D., CEO, Atrium Research & Consulting LLC 
• Mila McCurrach, Project Manager, NFPC, Neurofibromatosis Pre-Clinical Consortium, Children’s Tumor Foundation, Research Manager, Lustgarten Foundation 
• Myla Lai-Goldman, Ph.D., CEO, GeneCentric Diagnostics, Inc. 
• Nader Donzel, CTO, Biocartis  
• Nancy Allbritton, M.D., Ph.D., Professor & Chair, UNC/NCSU Department of Biomedical Engineering; Chair, UNC CASE; Department of Chemistry, Department of Pharmacology, University of North Carolina; Department of Materials Science & Engineering, North Carolina State University  
• Nathalie Scholler, M.D., Ph.D., Assistant Professor, Obstetrics and Gynaecology, Gyn University of Pennsylvania 
• Nathan Price, Ph.D., Associate Professor, Institute for Systems Biology 
• Nazneen Aziz, Ph.D., Director, Molecular Medicine, College of American Pathologists 
• Neal Goodwin, Ph.D., Director, Research and Development, in vivo Pharmacology Services, The Jackson Laboratory 
• Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp. 
• Nicolo Manaresi, Ph.D., CTO, Silicon Biosystems 
• Nils Gehlenborg, Ph.D., Research Associate, Center for Biomedical Informatics, Harvard Medical School 
• Nilsa C. Ramirez, M.D., Director, Surgical Pathology, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital; Medical Director, Biopathology Center, Co-I and Lead Pathologist, TCGA BCR, The Research Institute at Nationwide Children’s Hospital 
• Nitin S Patil, Scientist, Joint Unit-Molecular Oncology of Solid Tumors, DKFZ ( German Cancer Research Center) 
• Niven Narain, Ph.D., President and CTO, Berg Pharma 
• Noel S. Wilson, Ph.D., Senior Scientist I, Global Pharmaceutical Discovery, Hit to Lead, Abbott Laboratories 
• Oliver Schacht, Ph.D., CEO, Curetis AG 
• Pam Lucchesi, Ph.D., Director, Center for Cardiovascular and Pulmonary Research and Principal Investigator, Heart Center, The Research Institute at Nationwide Children’s Hospital 
• Patrick Schnell, M.D., Safety Risk Management Lead, Pfizer  
• Patrick Y. Mueller, Ph.D., Director, Global Coordinator, Novartis Institutes for BioMedical Research 
• Patrizia Paterlini-Brechot, Professor, Cell Biology & Oncology, University Paris Descartes, Paris; Director, INSERM Unit 807 & CSO, Rarecells 
• Paul Dempsey, Ph.D., Vice President, Bioengineering, Cynvenio Biosystems, Inc. 
• Paul Denny-Gouldson, Ph.D., Vice President, Translational Medicine, IDBS 
• Paul Holvoet, Ph.D., FAHA, FESC, Professor Biomedicine, Cardiovascular Diseases, KULeuven  
• Paul Konstant, Manager Informatics, Janssen Pharmaceuticals 
• Paul Polakis, Ph.D., Director & Staff Scientist, Cancer Targets, Genentech, Inc. 
• Paul Yager, Ph.D., The Hunter and Dorothy Simmons Endowed Chair, Department of Bioengineering, University of Washington   
• Peter Chu, Vice President, US Operations and Cancer Biology, Bionomics, Inc. 
• Peter Houghton, Ph.D., Principal Investigator, Hematology/Oncology & Blood and Marrow Transplant (BMT) and Director, Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital 
• Peter Kiener, Ph.D., President & CEO, Zyngenia, Inc. 
• Peter Kuhn, Ph.D., Associate Processor, Cell Biology, The Scripps Research Institute 
• Peter P. Lee, M.D., Professor and Associate Chair, Cancer Immunotherapeutics & Tumor Immunology (CITI), City of Hope and Beckman Research Institute, Beckman Center 
• Peter S. Miller, COO, Genomic Healthcare Strategies 
• Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics, Inc. 
• Peter Yu, M.D., Medical Oncologist and Hematologist, Palo Alto Medical Foundation; Chair, Health Information Technology Work Group, The American Society of Clinical Oncology; Co-Chair, Oncology Certification Work Group, Commission for the Certification of Health Information Technology 
• Phil Stephens, Ph.D., Vice President, Cancer Genomics, Foundation Medicine  
• Philip D. Cotter, Ph.D., Principal, ResearchDx 
• Philippe Corbisier, Ph.D., Scientific Project Manager, Reference Material Unit, European Commission 
• Phyllis Post, Executive Director, Merck & Co., Inc. 
• Pia Maria Gargiulo, Ph.D., Vice President, Pharma Partnerships, QIAGEN 
• Pierfausto Seneci, Ph.D., Professor, Chemistry, University of Milan 
• Premal Shah, Ph.D., Director, Business Development, Genomic Health, Inc. (tentative)  
• Raj Singh, Ph.D., President & CEO, Vivo Biosciences, Inc. 
• Rakesh Dixit, Ph.D., Vice President, Research & Development; Global Head, Biologics Safety Assessment, MedImmune 
• Ramesh Ramanathan, M.D., Medical Director, The Virginia G. Piper Cancer Center Clinical Trials  
• Ranjan Perera, Ph.D., Associate Professor and Scientific Director, Analytical Genomics and Bioinformatics, Metabolic Signaling & Disease, Sanford-Burnham Medical Research Institute 
• Raul Brauner, Founder and CEO, Oncotree and Biotree  
• Regina Gandour-Edwards, M.D., Director, Cancer Center Biorepository, Department of Pathology and Laboratory Medicine, UC Davis 
• Renier J. Brentjens, M.D., Ph.D., Associate Attending Physician, Associate Member, Department of Medicine, Memorial Sloan-Kettering Cancer Center 
• Richard A. Montagna, Ph.D., Senior Vice President, Corporate Business Development, RHEONIX, Inc. 
• Richard Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer 
• Richard C. Koya, M.D., Ph.D., Assistant Professor, Department of Surgery, Surgical Oncology, Member, JCCC Tumor Immunology Program Area 
• Richard Gill, Ph.D., Director & CEO, TruTouch Technologies, Inc. 
•  Richard E. Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer, La Jolla 
• Richard Levenson, M.D., Professor and Vice Chair for Strategic Technologies, Department of Pathology & Laboratory Medicine, University of California Davis Medical Center 
• Richard Ransom, Ph.D., Principal Investigator, Center for Clinical and Translational Research and Faculty, Nephrology and Urology Research Affinity Group, The Research Institute at Nationwide Children’s Hospital 
• Richard Selden, M.D., Ph.D., CEO, NetBio 
• Rob Mohney, Ph.D., Director, Projects (North American Pharma-Biotech), Metabolon, Inc. 
• Robert Dunstan, Distinguished Scientist, Investigative Histology, BiogenIdec 
• Robert J. Tressler, Ph.D., Vice President, Research & Development, Cellerant Therapeutics, Inc. 
• Robert L. Ferris, M.D., Ph.D., FACS, Professor and Chief, Division of Head and Neck Surgery; Associate Director, Translational Research; Co-Leader, Cancer,  Immunology Program, University of Pittsburgh Cancer Institute  
• Robin Polt, Ph.D., Professor of Chemistry & Biochemistry, BIO5, University of Arizona 
• Roman Kischel, M.D., Principal Scientist, BiTE Technology, Amgen Research (Munich) GmbH 
• Ronald Linnartz, Senior Director, External Collaborations, Oncology Correlative Sciences, Novartis Pharmaceuticals
• Ross Cagan, Ph.D., Professor, Developmental & Regenerative Biology, Mount Sinai School of Medicine 
• Rui Chen, Ph.D., Postdoctoral Scholar, Snyder Lab, Department of Genetics, Stanford University School of Medicine 
• Ryan Sasaki, Director, Global Strategy, ACD/Labs 
• S. Percy Ivy, M.D., Associate Branch Chief, IDB, CTEP, National Cancer Institute 
• Sabah Malek, Senior Regulatory Scientist, IVD/Medical Devices, Voisin Consulting Life Sciences 
• Sandor Szalma, Head, External Innovation, R&D IT at Janssen Research & Development, LLC  
• Sandra J. Horning, M.D., Senior Vice President, Global Head, Clinical Development Hematology/Oncology, Genentech 
• Sanjay Joshi, CTO, Life Sciences, Isilon Storage Division, EMC Corporation 
• Sarah Greene, Executive Director, Cancer Commons  
• Sarah P. Thayer, M.D., Ph.D., Associate Professor, Surgery, W. Gerald Austen Scholar in Academic Surgery & Director, Pancreatic  
• Saras Saraswathi Ph.D., Postdoctoral Research Associate, Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children’s Hospital 
• Scott Freedman, Co-Founder, Agile Diagnosis 
• Scott C. Johnson, Ph.D., Vice President, Product Development & Manufacturing, Luminex Corporation 
• Scott Kennedy, Ph.D., Global Head, Biomarker Development, Novartis Institutes for BioMedical Research 
• Scott McKeown, Ph.D., R&D Consultant, Randox Pharmaceutical Services, Randox Labs Ltd  
• Sergio E. Baranzini, Ph.D., Associate Professor, Heidrich Family and Friends Endowed Chair in Neurology, Department of Neurology, University of California San Francisco 
• Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Pre-Clinical Research, SAIC-Frederick, Inc.  
• Shan X. Wang, Ph.D., Professor of Materials Science & Engineering, jointly of Electrical Engineering, and by courtesy of Radiology (Stanford School of Medicine), Director, Stanford Center for Magnetic Nanotechnology  
• Sharad K. Verma, Ph.D., Investigator, Medicinal Chemistry, GlaxoSmithKline  
• Sharon Ungersma, Ph.D., Research Imaging Sciences, Amgen, Inc. 
• Shashikant Kulkarni, Ph.D., Associate Professor, Department Pathology & Immunology, Washington University School of Medicine  
• Shawn Levy, Faculty Investigator, HudsonAlpha Institute for Biotechnology  
• Shoibal Datta, Ph.D., Associate Director, R&D Information Technology, Biogen Idec 
• Shuqi Chen, Ph.D., CEO, IQuum, Inc. 
• Simon Bailey, Ph.D., Sr. Director, Worldwide Medicinal Chemistry Oncology, Pfizer  
• Simon Williams, Ph.D., Senior Scientist, Biomedical Imaging, Genentech 
• Sitharthan Kamalakaran, Ph.D., Senior Member, Research Staff, Philips Research North America 
• Soumitesh Chakravorty, Ph.D., Instructor, Center for Emerging Pathogens, NJMS, UMDNJ 
• Srinivasan Parthiban, Ph.D., CEO & President, Parthys Reverse Informatics 
• Stacy Feld, J.D., Partner, Physic Ventures 
• Stefan Roever, CEO & Founder, Genia Technologies 
• Stefan Scherer, M.D., Ph.D., Vice President, Clinical Development & Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG 
• Stefanie Jeffrey, M.D., John and Marva Warnock Professor, Department of Surgery, Chief of Surgical Oncology Research, Stanford University School of Medicine   
• Stephan Schürer, Ph.D., Center for Computational Science and Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami 
• Stephanie Faucette, Pharm.D., Ph.D., Senior Manager, Clinical Pharmacology, Millennium Pharmaceuticals 
• Stephen B. Squires, President, Quantum Materials Corporation 
• Stephen Hale, Ph.D.,Vice President, Drug Discovery, Ensemble Therapeutics 
• Stephen Little, Ph.D., Vice President, Personalized Healthcare, QIAGEN 
• Stephen A. Williams, M.D., Ph.D., CMO, SomaLogic, Inc 
• Steve Miller, M.D., Ph.D., Director, UCSF Clinical Microbiology Laboratory 
• Steve Olsen, M.D., Ph.D., Global Development Team Leader, Trastuzumab Emtansine Product Development-Oncology, Genentech, Inc. 
• Stuart Brown, Professor of Bioinformatics, New York University  
• Sue E. Siegel, Corporate Officer and CEO, healthymagination, GE 
• Sushmita Mukherjee, Ph.D., M.S., Assistant Professor, Biochemistry, Director, Multiphoton Microscopy Facility, Weill Medical College of Cornell University 
• Svetlana Amirova, Ph.D., Assistant Professor, Mathematics, University of Texas at El Paso 
• Syed A. Hashsham, Ph.D., Professor, Department of Civil and Environmental Engineering and Center for Microbial Ecology, Michigan State University 
• Sylvia L. Asa, M.D., Ph.D., Medical Director, Laboratory Medicine Program, University Health Network and Lakeridge Health; Senior
  Symposium 
• Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute 
• Terry Smith, Ph.D., Professor and Vice President for Research, Natural Sciences, National University of Ireland Galway 
• Theo McCormick, Director, Business Intelligence, Boston Heart Diagnostics 
• Thomas Krahn, Ph.D., Head, Global Biomarker Research, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG  
• Thomas Van Himbergen  Ph.D.,  Content Researcher & Manager,  Elsevier 
• Tibor van Rooij, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta; former Director of Bioinformatics, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre 
• Tim Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals 
• Todd Krueger, Strategy Leader, Medical Sciences, Life Technologies 
• Tom Plasterer, Ph.D., Principal Informatics Scientist, Semantic Framework Lead, AstraZeneca 
• Tom Scholl, Vice President, Research & Development, Integrated Genetics, LabCorp 
• Tom Willis, Ph.D., CEO, Sequenta, Inc. 
• Tony Blau, M.D., Professor, Department of Medicine/Hematology and Adjunct Professor, Department of Genome Sciences, University of Washington; Attending Physician, Seattle Cancer Care Alliance; Co-Director, Institute for Stem Cell and Regenerative Medicine, University of Washington and the Program for Stem and Progenitor Cell Biology at the UW/FHCRC Cancer Consortium; Founder and Scientific Officer, Partners in Personal Oncology   
• Jaspal Khillan, Ph.D., Associate Professor, Microbiology and Molecular Genetics, University of Pittsburgh 
• Topaz Kirlew, DBA, Vice President, Technical and Regulatory Affairs, Bio-Tissue 
• Toumy Guettouche, Ph.D., Hussman Institute for Human Genomics, Dr. John T. MacDonald Foundation Department of Human Genetics; Center for Genome Technology; Oncogenomics Core Facility, Sylvester Comprehensive Cancer Center, University of Miami, School of Medicine  
• Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG 
• Ulysses Balis, M.D., Ph.D., Associate Professor, Pathology, University of Michigan  
• Una Ryan, O.B.E., Ph.D., President and CEO, Diagnostics for All (DFA) 
• Valerie Speirs, Ph.D., Associate Professor, Leeds Institute of Molecular Medicine, University of Leeds 
•  Vladimir Zharov, Ph.D., D.Sc., Professor, Director, Arkansas Nanomedicine Center, University of Arkansas for Medical Sciences 
• Walter H. Koch, Ph.D., Vice President and Head, Global Research, Roche Molecular Diagnostics   
• Wayne Grody, M.D., Ph.D., FCAP, FACMG, Professor, Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, University of California Los Angeles School of Medicine 
• Weiwu He, Ph.D., CEO & President, OriGene Technologies, Inc 
• Wendy J. Levin, M.D., Director, Early Clinical Oncology, Pfizer 
• Wen-Tien Chen, Ph.D., Research Professor, Gynecologic Oncology, Stony Brook University Medical Center  
• William G. Loudon, M.D., Ph.D., Assistant Professor, Neurosurgery, University of California Irvine; Section Chief, Neurosurgery, Children’s Hospital of Orange County 
• William Pignato, Global Head, Regulatory Affairs, Novartis Institutes for BioMedical Research, Inc.                 
• William S. Dalton, Ph.D., M.D., CEO, M2Gen; Director, Personalized Medicine Institute, Moffitt Cancer Center 
• Winston Ho, Ph.D., President, Applied BioCode, Inc. 
• Yasuhiro Matsumura, M.D., Ph.D., Division of Developmental Therapeutics, National Cancer Center Hospital East, Tokyo, Japan 
• Yin Lin, Ph.D., Assistant Project Scientist, Biological Sciences, University of California, San Diego 
• Yukako Yagi, Ph.D., Director, MGH Pathology Imaging & Communication Technology (PICT) Center, Massachusetts General Hospital; Affiliated Faculty, Wellman Center for Photomedicine, Massachusetts General Hospital; Assistant Professor of Pathology, Harvard Medical SchoolYuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc. 
• Yuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc. 

*as of December 13, 2012, partial list